Posted on December 2, 2015 in Radiopharmaceutical News
The U.S. Food and Drug Administration (FDA) has approved Triad Isotopes' Abbreviated New Drug Applications (ANDA) for two PET radiopharmaceuticals: Fludeoxyglucose F18 (18F FDG), which is indicated for positron emission tomography (PET) imaging in Oncology, Cardiology and Neurology; and Sodium Fluoride F-18, which is indicated for imaging bone to define areas of altered osteogenic activity. For more information, see the package inserts and important safety information below.